Aug 14, 2026 06:46AM
Aug 13, 2026 04:04AM
Aug 12, 2026 06:50AM
Aug 6, 2026 06:51AM
Aug 6, 2026 06:50AM
Jul 22, 2026 06:50AM
Jul 22, 2026 06:50AM Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Jul 22, 2026 06:50AM
Jul 15, 2026 05:11AM
Jul 6, 2026 06:50AM
Jul 6, 2026 06:50AM
Jun 15, 2026 06:50AM
Jun 15, 2026 06:50AM
May 12, 2026 04:05PM Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
May 8, 2026 06:01AM
May 8, 2026 06:00AM
Apr 20, 2026 06:50AM
Apr 20, 2026 06:50AM
Apr 2, 2026 06:50AM
Mar 20, 2026 06:51AM
Mar 20, 2026 06:50AM Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
Mar 11, 2026 06:50AM
Mar 11, 2026 06:50AM
Mar 11, 2026 06:50AM
Mar 2, 2026 06:55AM
Mar 2, 2026 06:50AM
Jan 12, 2026 06:50AM
Jan 12, 2026 06:50AM Pharvaris Outlines 2026 Strategic Priorities
Dec 3, 2025 06:50AM
Dec 3, 2025 06:50AM
Nov 12, 2025 06:50AM
Nov 10, 2025 06:50AM
Aug 12, 2025 04:05PM
Jul 10, 2025 06:51AM
Jul 10, 2025 06:50AM Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025
Jun 16, 2025 06:50AM
Jun 16, 2025 06:50AM
Jun 2, 2025 06:52AM
Jun 2, 2025 06:50AM
May 13, 2025 04:05PM
Apr 7, 2025 06:58AM
Apr 1, 2025 06:50AM Pharvaris (PHVS) Granted Orphan Designation to Deucrictibant in the EU
Apr 1, 2025 06:50AM
Mar 3, 2025 06:50AM
Mar 3, 2025 06:50AM
Jan 13, 2025 06:52AM
Jan 13, 2025 06:50AM
Nov 13, 2024 04:10PM
Oct 24, 2024 08:00AM Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting
Sep 5, 2024 06:50AM

329,915 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All